Three conditions keep turning up in the same patients: addiction, chronic pain, and type 2 diabetes.
Conventional care treats them in three different buildings. An addiction specialist, a pain physician, an endocrinologist — each with a separate plan, often unaware of what the others are doing.
The argument here is that this fragmentation is a mistake, because the three conditions share a substrate. Treating them together works better than treating them separately.
Why these three cluster together
Start with the observation rather than the theory: these conditions co-occur far more often than chance would predict.
People with chronic pain have elevated rates of substance use disorder. People with type 2 diabetes have elevated rates of chronic pain. People in recovery from addiction have high rates of metabolic disease. Each pairing is well documented.
The usual explanation is circumstantial — pain leads to opioid prescribing, which leads to dependence; diabetes causes neuropathy, which causes pain; addiction disrupts the lifestyle that would prevent diabetes. All of that is real and explains part of it.
But it does not explain the whole pattern, and it treats each link as an accident rather than a shared cause.
The shared substrate
The proposed common ground is metabolic dysfunction, and specifically the state of chronic inflammation and disordered reward signalling that accompanies it.
Consider what these three conditions have in common at the level of mechanism:
- Inflammation. Systemic low-grade inflammation is central to type 2 diabetes, amplifies pain through central sensitization, and is increasingly implicated in the neurobiology of substance use disorder.
- Dopamine and reward. Insulin acts in the brain, including in regions that govern reward. Highly processed, rapidly absorbed food engages reward circuitry through pathways that overlap with those involved in addiction.
- Dysregulated stress physiology. The HPA axis is disrupted in all three, and that disruption feeds inflammation, appetite dysregulation, sleep disruption and craving alike.
None of this means the three conditions are the same disease. It means they draw on overlapping physiology, so an intervention aimed at that overlap can move more than one of them.
I want to be careful here, because this is where this kind of argument usually overreaches. The mechanistic overlap is real and reasonably well described. The claim that treating the metabolic substrate is the most effective route for all three is a clinical position — mine — informed by practice, not a conclusion from a randomised trial comparing integrated against fragmented care. No such trial exists.
What treating them together looks like
In practice, integration means a few concrete things.
The metabolic assessment happens regardless of which door the patient came through. Someone presenting with pain gets fasting insulin, triglyceride-to-HDL and HbA1c looked at, not only imaging.
Dietary change is treated as a therapeutic intervention with a dose and a monitoring plan, not as generic advice at the end of a visit.
Opioid decisions are made in the context of the whole picture. This practice weans patients off opioids rather than escalating them — and the metabolic work is part of what makes tapering tolerable, because a less inflamed nervous system is a less reactive one.
And progress is measured with numbers in all three domains — glucose and insulin markers, a pain and function measure, and substance use — so improvement in one is visible against the others.
Why fragmentation actively hurts
Separate treatment is not merely inefficient. It can work against itself.
Medication for one condition can worsen another. Some psychiatric and pain medications drive weight gain and worsen insulin resistance. Corticosteroid injections raise blood glucose for several days. Escalating opioids can produce hyperalgesia — more pain from more drug — while doing nothing about the metabolic driver underneath.
When three physicians each optimise their own outcome without visibility into the others, the patient absorbs the interactions.
Frequently asked questions
Are addiction, chronic pain and diabetes really the same condition?
No. They are distinct diagnoses with distinct criteria and treatments. The argument is that they share substantial underlying physiology — inflammation, disrupted reward signalling and dysregulated stress response — which is why they co-occur so often and why addressing that shared layer can improve more than one at a time.
Is integrated treatment proven better than seeing three separate specialists?
Not by a randomised trial — no study has compared integrated against fragmented care for this triad, and I will not claim otherwise. The mechanistic case is strong and it is how this practice is organised, but it is a clinical position rather than a proven protocol. Individual results vary.
Does this mean my pain medication caused my diabetes?
Not directly, but interactions are real and worth reviewing. Some medications used for pain and mood promote weight gain and worsen insulin resistance, and corticosteroid injections raise blood glucose temporarily. That is a reason to review your whole medication list with one physician who can see all of it — not a reason to stop anything. Do not start, stop, or change any medication without consulting your physician.
Do you prescribe opioids for chronic pain?
This practice works to reduce and discontinue opioids rather than escalate them, because escalating doses can produce hyperalgesia — increased pain sensitivity caused by the medication itself. Any change to an opioid regimen must be supervised; abrupt or unsupervised discontinuation is dangerous.
Where can I be evaluated for all three together?
Padda Institute Center for Interventional Pain Management is at 4477 Woodson Road, Suite 100, St. Louis, MO 63134, next to St. Louis Lambert International Airport, with a second location at 12174 Natural Bridge Road, Bridgeton, MO 63044. The practice serves the St. Louis region across Missouri and Illinois. Call (314) 481-5000 or text (314) 886-5902, Monday to Friday, 8:00 AM to 5:00 PM.
Key takeaways
- Addiction, chronic pain and type 2 diabetes co-occur far more than chance predicts.
- They share inflammation, reward-signalling disruption and stress-axis dysregulation.
- Treating the shared metabolic layer can move more than one condition at once.
- Fragmented care lets treatments for one condition worsen another.
- Integration is a well-reasoned clinical position, not a trial-proven protocol.
Medically reviewed by Gurpreet Singh Padda, MD — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.
This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. To be evaluated, request an appointment or call (314) 481-5000.
References
- Araújo J, Cai J, Stevens J. Prevalence of optimal metabolic health in American adults: NHANES 2009–2016. Metabolic Syndrome and Related Disorders. 2019;17(1):46–52.
- Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–S15.
- Feinman RD, Pogozelski WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015;31(1):1–13.
- Malhotra A, DiNicolantonio JJ, Capewell S. It is time to stop counting calories, and time instead to promote dietary changes. Open Heart. 2015;2(1):e000273.
Get evaluated by a physician who treats the terrain, not just the signal
Chronic pain, metabolic disease and trauma physiology reinforce each other. At the Padda Institute they are assessed together, because treating one alone underperforms.
Or call or text (314) 481-5000.
Dr. Gurpreet Singh Padda, MD, MBA, MHP
